PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026JCEM Case Reports0 citationsOpen Access

Transoral videolaryngoscopic surgery for hypopharyngeal anaplastic metastasis from papillary thyroid carcinoma

View Full Paper
YYYuya YokoyamaNNNaoki NishioMSMai Sugiura

Key Points

  • To evaluate the effectiveness of transoral videolaryngoscopic surgery combined with targeted therapy for hypopharyngeal metastasis from papillary thyroid carcinoma.
  • Case report of a 78-year-old man with hypopharyngeal metastasis and prior papillary thyroid carcinoma.
  • Surgery utilized transoral videolaryngoscopic techniques to remove the tumor.
  • Postoperative genetic testing identified the BRAF V600E mutation, leading to targeted therapy.
  • Targeted therapy included encorafenib and binimetinib, initiated 24 days after surgery.
  • No evidence of recurrent disease observed six months post-surgery and therapy.
  • Patient's swallowing function was preserved, and quality of life improved.
  • Successful closure of the tracheostomy after local tumor control.

Abstract

Abstract We report an extremely rare case of hypopharyngeal metastasis with anaplastic transformation (anaplastic thyroid carcinoma) originating from papillary thyroid carcinoma, demonstrating successful tumor control using minimally invasive transoral surgery combined with targeted therapy. A 78-year-old man with a history of papillary thyroid carcinoma treated with total thyroidectomy and radioactive iodine 10 years earlier presented with sore throat and difficulty swallowing. Fiberoptic examination revealed a 25-mm mass on the posterior hypopharyngeal wall causing airway compromise, necessitating an emergency tracheotomy. Biopsy confirmed hypopharyngeal metastasis with anaplastic thyroid carcinoma. Given his comorbidities (chronic leukemia, severe pulmonary arterial hypertension), he underwent transoral videolaryngoscopic surgery to achieve local tumor control while preserving swallowing function. Postoperative genetic testing detected a BRAF V600E pathogenic variant, leading to treatment with encorafenib and binimetinib, initiated on postoperative day 24. Six months after surgery and targeted therapy, fiberoptic examination and contrast-enhanced computed tomography showed no evidence of recurrent disease; the tracheostomy was closed, and the patient maintained normal swallowing and quality of life. This case illustrates that a surgery-first, function-preserving approach integrated with early molecular-targeted BRAF/MEK inhibition can achieve durable local control and maintain laryngopharyngeal function, even when anaplastic transformation occurs within a hypopharyngeal metastatic focus.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yokoyama et al. (2026) studied this question.

synapsesocial.com/papers/69994cc2873532290d0218dchttps://doi.org/10.1210/jcemcr/luag003
Ask AI
Helpful
Bookmark
Share
View Full Paper